Oncologist Robert Whitfield tests scar capsule tissue during implant removal to detect cancer recurrence and bacterial contamination. He found bacterial contamination in 29% of patients and has identified several breast cancers and lymphomas using this protocol.
The patient's scar capsule.
29%
I always look at every cancer patient with the same lens. I would want my sister taken care of, was looking for a recurrence. So when you take things out, it's incumbent upon somebody who did oncology as a career to look for that. And that that always should be looked at, because I found a handful of breast cancers that way. Lymphoma. And then, as I said, we test every single patient's scar capsule. So once again, it's not the implant, it's the patient's tissue that gets tested. Because that's what's important. That in 29% of the patients will reveal a bacterial contamination. And people ask me, well, do you trust that number? Do you believe that? Well, yes. I take the sample, right? I sent it to the company. You collect the data, runs the sample.
